HLA-A*03:01&B2M&KRAS WT (VVVGAGGVGK) Tetramer Protein, Human, MHC (His & Avi)

Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.

Pack Size	Availability	Price/USD	Quantity
100 μg	Inquiry	$ 489.00
1 mg	Inquiry	$ 3,265.00

Pack Size

Availability

Price/USD

Quantity

100 μg

Inquiry

$ 489.00

1 mg

Inquiry

$ 3,265.00

Description

Species	Human
Expression System	HEK293 Cells
Tag	C-His-Avi
Accession Number	NP_002107.3(HLA-A*03:01)&P61769(B2M)&VVVGAGGVGK
Synonyms	NS, NS3, KRAS2, RASK2, MHC, RALD, K-Ras 2, K-RAS4B, C-K-RAS, KI-RAS, K-RAS4A, K-RAS2B, K-RAS2A, GTPase Kras, KRAS, CFC2, KRAS1
Construction	Gly25-Thr305(HLA-A*03:01), Ile21-Met119(B2M) and VVVGAGGVGK peptide. Tetramer is assembled by biotinylated monomer and streptavidin.
Protein Purity	> 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC

Endotoxin	< 1 EU/μg by the LAL method.
Formulation	Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS (pH 7.4). Typically, 8% trehalose is incorporated as a protective agent before lyophilization.
Reconstitution	Reconstitute the lyophilized protein in distilled water. The product concentration should not be less than 100 μg/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing.
Stability & Storage	Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at-80℃. For reconstituted proteinsolutions, the solution can be stored at -20°c to -80'c for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.
Shipping	In general, Lyophilized powders are shipping with blue ice. Solutions are shipping with dry ice.
Research Background	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.